[Please note that this page contains affiliate links. If you choose to purchase after clicking a link, I may receive a commission at no extra cost to you.]
Invented by a new biotech company based in Calgary, Alberta, called MagicMed Industries, it creates “Psybary,” a large assortment of molecules that closely resemble psychedelics.
The Green Market Report includes 12 patents related to 9 separate drug categories for 125 million individual molecules.
Artificial Intelligence in medicine gains traction, and it won’t be long before AI starts synthesizing better treatments to replace and or improve the medicine cabinet.
Artificial Intelligence Creating Medicine
It may seem like a boatload worth of drugs, and it may be.
However, most of them are the tiniest atomic variation on well-established entheogens such as Psilocybin.
Researchers are unsure if most of these analogs are psychoactive and can even treat mental health issues.
As research is in its early stages, researchers are making significant developments by utilizing machine learning and artificial intelligence to sort through millions of various derivatives, analogs, and drugs of psychedelics.
Typically, pharmaceutical corporations concentrate on making one drug for a single condition at a time.
Now, using cutting-edge computer science, as Artificial Intelligence in medicine enters the consciousness of some scientists, are creating many hypothetical psychedelics—or pharmaceuticals that closely relate to psychedelics.
In early March 2021, MagicMed launched their PsyAI program, recruiting Dr. Eric Nyberg, a professor at Carnegie Mellon University.
His intelligence helped develop the original IBM Watson computer system, which famously won on the game show Jeopardy!
The newly formed MagicMed company anticipations employing Nyberg’s tech to filter through these millions of compound designs to find meds that may work like psychedelics and nootropics for treating various ailments.
Others, such as molecular pharmacologist Dr. Bryan Roth at the University of North Carolina-Chapel Hill, also use Artificial Intelligence in Medicine to produce new psychedelic meds.
DARPA (the Defense Advanced Research Projects Agency), the United States military’s secretive developmental department of intelligence, recently gave Dr. Roth $27 million to develop drugs like psychedelics without causing the psychoactive ‘trip’ properties.
The lab run by Dr. Roth uses a computer program named Ultra-Large-Scale Docking that produces millions of variations of different chemical arrangements.
It predicts how the particles would resemble the serotonin 2A receptor.
It is mainly connected with how some psychedelics have their specific mental outcomes.
AI Creating a New Class of Psychedelics
DMT, LSD, and Psilocybin all bind to the serotonin 2A receptor.
Dr. Bryan Roth has done some of the world’s most important research on how these drugs, such as LSD, interact with these receptors and can be used in psychedelic psychotherapy.
Dr. Roth’s team has carefully chosen substances that seem hopeful new medications and works with an intelligence lab to synthesize them.
Then, finally, artificial intelligence tests the new chemicals by squirting them on human cells to determine what the AI predicted matches.
Dr. Roth says he and his colleagues call these new compounds “neuro transformational medicines“ as they are a new class of meds that psychiatry has never seen.
This, of course, raises the big question of whether these new compounds will work, but the implications are substantial.
Machine Learning AI
However, machine learning and artificial intelligence are quickly evolving drug development, not only for entheogens but also for the pharmaceutical industry.
For example, in November 2020, DeepMind, (is owned by Alphabet Inc., the same company that owns Google) had solved protein folding, a longtime enigma that has troubled biology for over 50 years.
Protein folding uses computers to calculate a protein’s three-dimensional structure constructed on its amino acids.
Now that it has been solved, it will make it a lot simpler to predict how new pharmaceuticals will interact with receptors.
“Our goal is to alleviate human suffering ultimately,” Roth explains.
A goal I wanted to see before I died was legal weed (which happened in 2018). As Artificial Intelligence in medicine produces more psychedelics, I want to see everyone’s medicine cabinets replaced by their psychedelic counterparts.
MagicMed’s PsyAI Program